HC Wainwright Issues Positive Estimate for Annexon Earnings

Key Points

• HC Wainwright raised its Q1 2026 EPS estimate for Annexon to ($0.31) from ($0.36) and provided multi-year loss-reduction forecasts (FY2026: ($1.22), FY2027: ($0.94), FY2028: ($0.55), FY2029: ($0.05)), signaling an improving earnings outlook.
• Analysts hold a consensus “Moderate Buy” rating with a $17.00 price target while Annexon shares trade around $5.85 (market cap ≈ $938M), highlighting a large gap between current price and analyst target.
• Annexon recently beat quarterly expectations (reported ($0.28) vs. est. ($0.32)), although insiders have sold shares (32,513 shares worth ~$166k in the last 90 days) and now own 11.87% of the company.

Annexon, Inc. (NASDAQ:ANNX - Free Report) - Analysts at HC Wainwright boosted their Q1 2026 earnings estimates for shares of Annexon in a research report issued on Thursday, April 2nd. HC Wainwright analyst A. Ghosh now anticipates that the company will post earnings per share of ($0.31) for the quarter, up from their prior estimate of ($0.36). The consensus estimate for Annexon's current full-year earnings is ($0.96) per share. HC Wainwright also issued estimates for Annexon's Q2 2026 earnings at ($0.31) EPS, Q3 2026 earnings at ($0.30) EPS, Q4 2026 earnings at ($0.30) EPS, FY2026 earnings at ($1.22) EPS, FY2027 earnings at ($0.94) EPS, FY2028 earnings at ($0.55) EPS and FY2029 earnings at ($0.05) EPS.

ANNX has been the topic of a number of other research reports. Chardan Capital reissued a "buy" rating and issued a $16.00 price target on shares of Annexon in a research note on Friday, March 20th. Weiss Ratings reissued a "sell (d-)" rating on shares of Annexon in a research note on Wednesday, January 21st. Finally, Cantor Fitzgerald restated an "overweight" rating on shares of Annexon in a report on Wednesday, January 14th. Five research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Annexon presently has a consensus rating of "Moderate Buy" and a consensus price target of $17.00.

Annexon Stock Performance

Annexon stock traded up $0.05 during trading on Tuesday, reaching $5.85. The company had a trading volume of 909,555 shares, compared to its average volume of 2,675,806. The firm's 50-day simple moving average is $5.51 and its 200 day simple moving average is $4.64. Annexon has a 1-year low of $1.28 and a 1-year high of $7.18. The firm has a market capitalization of $937.95 million, a PE ratio of -4.30 and a beta of 1.14.

Annexon (NASDAQ:ANNX - Get Free Report) last released its quarterly earnings results on Monday, March 30th. The company reported ($0.28) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.32) by $0.04.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Mirae Asset Global Investments Co. Ltd. raised its holdings in shares of Annexon by 65.6% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 7,033 shares of the company's stock worth $35,000 after acquiring an additional 2,785 shares during the period. Landscape Capital Management L.L.C. purchased a new position in shares of Annexon during the 4th quarter worth $50,000. CIBC Bancorp USA Inc. purchased a new position in shares of Annexon during the 3rd quarter worth $31,000. Mercer Global Advisors Inc. ADV purchased a new position in shares of Annexon during the 4th quarter worth $52,000. Finally, Mount Vernon Associates Inc. MD purchased a new position in shares of Annexon during the 4th quarter worth $53,000.

Insider Buying and Selling

In other Annexon news, EVP Michael Overdorf sold 6,225 shares of the firm's stock in a transaction on Wednesday, February 18th. The stock was sold at an average price of $5.10, for a total value of $31,747.50. Following the transaction, the executive vice president owned 124,464 shares in the company, valued at approximately $634,766.40. This trade represents a 4.76% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, EVP Dean Richard Artis sold 5,290 shares of the firm's stock in a transaction on Wednesday, February 18th. The shares were sold at an average price of $5.10, for a total value of $26,979.00. Following the completion of the transaction, the executive vice president owned 123,487 shares in the company, valued at $629,783.70. The trade was a 4.11% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 32,513 shares of company stock worth $165,973 in the last ninety days. Company insiders own 11.87% of the company's stock.

About Annexon

Annexon Inc is a clinical-stage biotechnology company focused on the discovery and development of complement-targeted therapies for patients with neurodegenerative and neuroimmune diseases. The company's research platform centers on the inhibition of the C1 complex, a key initiator of the classical complement pathway implicated in several rare and life-threatening disorders. By selectively targeting upstream complement activation, Annexon aims to prevent the aberrant immune-mediated damage that characterizes conditions such as Guillain-Barré syndrome (GBS) and autoimmune neuropathies.

At the core of Annexon's pipeline is ANX005, a humanized monoclonal antibody directed against the C1q subcomponent, currently in Phase 2 clinical trials for acute GBS and chronic neurodegenerative indications.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.